pathophysiology: alzheimer's disease

Post on 07-May-2015

2.063 Views

Category:

Documents

2 Downloads

Preview:

Click to see full reader

DESCRIPTION

This presentation was given to first year pharmacy students as part of course on medical physiology and pathophysiology.

TRANSCRIPT

Alzheimer’s Disease

Brian J. Piper, Ph.D., M.S.

October 24, 2012

PiB PET scan

Disease Identifier Frequency in US Genetic Patho-physiology

Neurochem

PharmManagement

Parkinson’s JamesParkinson1817

500 K low nigra-striatal

DA common

Alzheimer’s AloysiusAlzheimer1906

5.4 million moderate diffusecortex

ACh? common

Huntington’s GeorgeHuntington1872

30 K high striatum ? uncommon

ALS JeanMartinCharcot

25 K low motorneurons

Glut? common

ACh: acetylcholine; DA: dopamine; Glu: glutamine; sym: symptom management

Neurodegenerative Disorders

Aloysius ”Alois” Alzheimer

• German psychiatrist• Described symptoms + pathology

– Neuronal loss– Plaques– Tangles

• Presentation to SW German Psychiatrist meeting about Auguste Deter ignored butEmil Kraeplin

Cipriani et al. (2011) Neurological Sciences, 32(2), 275-279.

1864-1913

1st, but possibly, atypical case Auguste Deter, 1851-1906

Alzheimer’s Prevalence

Year Patients (millions)

2010 5.8

2020 6.8

2030 8.7

2040 11.8

2050 14.3

Dementia cases in U.S.

Qui et al. (2009). Dialogues in Clinical Neuroscience, 11(2), 111-128.

Healthy Alzheimer’s Disease

AD, coronal cross section

AD, external aspect

AD ≠ Aging

Smith & Jobst (1996). British Medical Bulletin, 52(3), 575-586.

Rate of Decline

Smith & Jobst (1996). British Medical Bulletin, 52(3), 575-586.

Alzheimer’s Disease (AD)

• nucleas basilis is one region affected early• somas for acetylcholine system

Stahl (2008). Essential Psychopharmacology. p. 921.

Genetic Risk Factors

• Late Onset AD• Apolipoprotein E:

– Chromosome 19– 299 amino acids– E3 > E2 > E4

Isoform 112 158

E2 Cysteine Cysteine

E3 Cysteine Arginine

E4 Agrinine Agrinine

Apolipoprotein E & Alzheimer’s Disease

• ε4– 1 copy: 2.5x– 2 copies: 7x

Corder et al. (1993). Science, 261, 921-3.

Test of Neurocognitive Function

• Mini-Mental State Exam (MMSE)– Where are we in?– Count backwards by 7 starting with 100– Remember 3 words– Copy drawing

• Executive function

Folstein, Folstein, & McHugh (1975). J Psychiatric Research, 12, 189-198.

Behavior & Brain

Smith & Jobst (1996). British Medical Bulletin, 52(3), 575-586.

Executive Function Test: Tower of London• Developed by Tim

Shallice in 1982 as a simplified version of the Tower of Hanoi

• Test of problem solving which is sensitive to brain damage

Screen shot from Piper et al. (2012). Behavior Research Methods, 44(1), 110-123.

DSM5 Criteria For Neurocognitive Disorder

http://www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx?rid=421

Amyloid Plaque

• Amyloid Beta Peptide: 40/42 amino acids• Amyloid Plaque: clusters of Beta amyloid +

Pittsburg Compound B (PIB): A Future Diagnostic Biomarker for AD?

Alzheimer’s Vaccine?

• Immunization against AB42 peptide produced antibodies

• MMSE– 30: maximum– 21-24: mild– 10-20: moderate– <9: severe

• Brain versus behavior

Holmes et al. (2008). Lancet, 372, 216-223.

Alzheimer’s Vaccine?

• Immunization against synthetic AB42 produced antibodies

• MMSE– 30: maximum– 21-24: mild– 10-20: moderate– <9: severe

• Brain versus behavior

Holmes et al. (2008). Lancet, 372, 216-223.

top related